Phase 2 Myeloid Clinical Trials
256 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 256 trials
Recruiting
Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
National Cancer Institute (NCI)153 enrolled177 locationsNCT05554393
Recruiting
Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm+1 more
National Cancer Institute (NCI)335 enrolled220 locationsNCT05554406
Recruiting
Phase 2
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
National Cancer Institute (NCI)147 enrolled220 locationsNCT06317649
Recruiting
Phase 2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled346 locationsNCT05564390
Recruiting
Phase 1Phase 2
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
Myeloid Malignancies
M.D. Anderson Cancer Center42 enrolled1 locationNCT06930651
Recruiting
Phase 2Phase 3
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+1 more
Taiho Oncology, Inc.316 enrolled71 locationsNCT04256317
Recruiting
Phase 2
Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid LeukemiaRelapse/Recurrence
Shenzhen University General Hospital10 enrolled1 locationNCT07563179
Recruiting
Phase 1Phase 2
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Myeloid Leukemia, Philadelphia Positive
Novartis Pharmaceuticals34 enrolled39 locationsNCT04925479
Recruiting
Phase 2Phase 3
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Acute Myeloid Leukaemia (AML)
Moleculin Biotech, Inc.312 enrolled25 locationsNCT06788756
Recruiting
Phase 1Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 2
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
National Cancer Institute (NCI)93 enrolled122 locationsNCT06672146
Recruiting
Phase 2
Ivosidenib as Post-HSCT Maintenance for AML
Acute Myeloid Leukemia (AML)IDH1 MutationHematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital75 enrolled4 locationsNCT06707493
Recruiting
Phase 1Phase 2
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Acute Lymphoblastic LeukaemiaAcute Myeloid Leukaemia
AstraZeneca84 enrolled30 locationsNCT07155226
Recruiting
Phase 1Phase 2
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Acute Myeloid LeukemiaMyeloid Malignancy
Benjamin Tomlinson20 enrolled2 locationsNCT06129734
Recruiting
Phase 1Phase 2
Multiple CAR-T Cell Therapy Targeting AML
Acute Myeloid Leukemia
Shenzhen Geno-Immune Medical Institute10 enrolled1 locationNCT04010877
Recruiting
Phase 1Phase 2
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center52 enrolled1 locationNCT04128748
Recruiting
Phase 1Phase 2
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
Acute Myeloid Leukemia
Shenzhen Geno-Immune Medical Institute10 enrolled3 locationsNCT03222674
Recruiting
Phase 2
Study of SA+X in the Treatment of Newly Diagnosed AML
Acute Myeloid Leukemia
Ruijin Hospital205 enrolled1 locationNCT07548710
Recruiting
Phase 1Phase 2
A Study of BGB-11417 in Participants With Myeloid Malignancies
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
BeiGene260 enrolled46 locationsNCT04771130
Recruiting
Phase 2
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center140 enrolled1 locationNCT06811233